Sarah B. Goldberg

TL;DR: It is shown that PD-L1 expression is associated with recurrence in patients diagnosed with metastatic lung cancer and the use of immune checkpoint inhibitors to correct this association is a viable strategy for treating these patients.

TL;DR: Identification of tumor-specific DNA in the CSF and correlation of these findings with CSF cytokine profiles might enable minimally invasive monitoring of treatment response and failure, which is particularly important in the era of targeted and immunotherapies where radiographic changes are becoming increasingly difficult to interpret.

TL;DR: Final Phase I results of a Phase I/II prospective trial assessing safety and tolerability of SBRT and concurrent pembrolizumab are reported.